Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide is expected within weeks.
Liraglutide is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high, and by inhibiting appetite.
In Europe, Novo Nordisk received marketing authorization for liraglutide under the brand name Victoza® on 30 June 2009.
